BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3184485)

  • 1. [Role of PDGF on myeloproliferative disorders].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
    Yonekura S
    Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
    [No Abstract]   [Full Text] [Related]  

  • 3. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 4. Myelofibrosis in myeloproliferative disorders.
    Srinivasan U; Talvalkar GV; Advani SH
    Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
    Kimura A; Katoh O; Kuramoto A
    Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelofibrosis: a role for platelet derived growth factor (PDGF)?
    Romano M; Poggi A
    Haematologica; 1986; 71(5):359-61. PubMed ID: 3096830
    [No Abstract]   [Full Text] [Related]  

  • 9. [Atypical myeloproliferative disorders: a study on 3 cases showing pancytopenia, marrow fibrosis and the absence of splenomegaly].
    Yoshida Y; Yamagishi M; Fukuhara S; Sawada H; Ohkuma M; Uchino H; Nakamura T
    Rinsho Ketsueki; 1984 Mar; 25(3):383-92. PubMed ID: 6471435
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
    Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
    J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
    Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
    Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
    Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
    Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet-derived growth factor: mechanism of action and role in the development of diseases].
    Almazov VA; Blagosklonnyĭ MV; Zaritskiĭ AIu
    Ter Arkh; 1984; 56(7):144-7. PubMed ID: 6385321
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of growth factors of platelets (PDGF, TGF-beta, EGF) in the pathogenesis of myelofibrosis].
    Kimura A; Katoh O; Kuramoto A
    Rinsho Byori; 1989 Apr; Spec No 81():1-8. PubMed ID: 2787864
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
    Nagao T; Yonekura S
    Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
    [No Abstract]   [Full Text] [Related]  

  • 19. [Basic and clinical study of platelet-derived growth factor gene expression].
    Takimoto Y; Kimura A
    Rinsho Ketsueki; 1994 Apr; 35(4):364-9. PubMed ID: 8028181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelofibrosis in the myeloproliferative disorders.
    Ellis JT; Peterson P
    Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.